All News
Coffee with milk may have an anti-inflammatory effect
EurekAlert!
Can something as simple as a cup of coffee with milk have an anti-inflammatory effect in humans? Apparently so, according to a new study from the University of Copenhagen. A combination of proteins and antioxidants doubles the anti-inflammatory properties.
Read Article
Simon Says “Don’t Do This” (1.27.2022)
Dr. Jack Cush reviews this week’s journal articles, focuses on studies that should not have been done and responds to viewer questions in Ask Cush Anything.
Read Article
PsA Til Death Do Us Part (1.20.2023)
Dr. Jack Cush reviews the highlights from the past week on RheumNow.com.
Read Article
Hydroxychloroquine Dose and Risk for Incident Retinopathy
A cohort study in Annals of Internal Medicine shows that higher hydroxychloroquine doses was associated with progressively greater risk for incident retinopathy.
Read Article
Is JAKi therapy safe in RA-ILD pts? Italian retrospective study (2018-June 2022) w/ 43 RA pts & HRCT proven ILD (med age 69yrs) & Rx w/ JAKi. After 19 mos F/U, the FVC was stable in 79%, improved in 11%, & worse in 11%. DLCO & HRCT trend was similar. https://t.co/T0rP96FM0Z https://t.co/W8NFtfevQg
Links:
Dr. John Cush RheumNow ( View Tweet)
FDA has approved the 1st BTK (Bruton’s tyrosine kinase) inhibitor (Jaypirca™ or pirtobrutinib) for adults with refractory mantle cell lymphoma. BTK inhibitors are also being developed for use in MS, RA, SLE, pemphigus & more https://t.co/599tK21H1Z https://t.co/KSqMMDWmfd
Links:
Dr. John Cush RheumNow ( View Tweet)
Feb 3rd, today is #NationalWomenPhysiciansDay. The date honors Dr. Elizabeth Blackwell, 1st woman to receive an MD United States (1849). RheumNow will devote the whole month of April 2023 to our Campaign on Women in Rheumatology - stay tuned! https://t.co/l1M56L8h9N https://t.co/eQpetW02CE
Links:
Dr. John Cush RheumNow ( View Tweet)
PNAS has a novel approach to #RA Tx; bioengineered probiotic(Lactobacillus reuteri) orally delivers a peptide Kv1.3 channel blocker to RxRA. Kv1.3 is expressed on CCR7− effector memory T cells. Blocking Kv1.3 improves RA & PSO in rat models. https://t.co/DyyXi2GUH2 https://t.co/8nDyFv9DWx
Links:
Dr. John Cush RheumNow ( View Tweet)
Swiss RA registry assessed outcomes after 1st JAKi. 400 RA pts starting/failing JAKi were switched to 2nd JAKi or TNFi or other MOA biologic. ~40% had prior bDMARDs. Retention was higher w/ 2nd JAK (918d)i vs other options. TNFi (335d) or OMA (918d). https://t.co/3A3KwVcTCN https://t.co/UFLPGfmzNv
Links:
Dr. John Cush RheumNow ( View Tweet)
Rheumatic Disease - IBD Overlap
Nearly one in 10 patients with IBD also have rheumatologic disorders, meaning that specialists have to talk to each other to develop a treatment plan that works for both conditions, a researcher suggested.
https://t.co/s3u9q8Sw9Y https://t.co/RjFyEcm6FA
Links:
Dr. John Cush RheumNow ( View Tweet)
JAK-pot Study: To Cycle or Switch after JAK inhibitor Failure?
Data from 17 international registries suggest that for RA patients failing their first JAKi, it did not matter if they were cycled to another JAKi or switched to a bDMARD.
https://t.co/WunRxeF5Wm https://t.co/cOIjglnPNU
Links:
Dr. John Cush RheumNow ( View Tweet)
Early Ph IIa study of ATI-450 (Zunsemetinib), an investigational selective MAP kinase–2 (MK2) blocker leds to a sustained antiinflammatory effect; studied in 19 RA pts w/ ACR 20/50/70 of 60%/33%/20% at wk 12. https://t.co/IyjJCgdXG2
Links:
Dr. John Cush RheumNow ( View Tweet)
Have a Rheumatology question or case for Jack Cush? Record it here and we may feature it on an upcoming podcast. Tell us your name and where you practice rheumatology.
https://t.co/RaFKTqhQjN https://t.co/hH0NcpOoyx
Links:
Dr. John Cush RheumNow ( View Tweet)
Korean study of 439 RA pts starting JAKi, TNFi or non-TNFi. Physician choice of JAKi was more likely with age (OR 1.03), no pulmonary Dz (OR 0.07), Higher Dz activity (OR 1.80) & prior tacrolimus (OR 2.05) https://t.co/9Vv5XfzfrH https://t.co/59Whi7tCIE
Links:
Dr. John Cush RheumNow ( View Tweet)
Causes of Enthesitis: SpA (AS, reactive arthritis, PsA, enteropathic arthritis, ERA), JIA, but also in RA, leprosy, trauma, OA, DISH, acromegaly, fluorosis, retinoid therapy, hypo- or hyper-PTH, POEMS syndrome, X-linked hypophosphatemia https://t.co/pff2OWBT5C https://t.co/7zm2la4GtD
Links:
Dr. John Cush RheumNow ( View Tweet)
Rx failures w/ nonmedical switching of biosimilars may be Nocebo effect. 140 #RA pts, 51 non-switchers & 89 switchers. Non-switchers more likely to improve than switchers (68 vs 26%, p < 0.001) and less likely to worsen (1% vs 9%, p < 0.01). https://t.co/w8lnv1V5Pi https://t.co/iT2RkkSosl
Links:
Dr. John Cush RheumNow ( View Tweet)
Worldwide prevalence (major markets) of #RA was 4.9 million in 2020; the RA global treatment market is estimated at US $40.5 billion in 2021, and is expected to grow ~6% per year in the next decade. https://t.co/EtBQwru0uF https://t.co/BRLtnwxc2b
Links:
Dr. John Cush RheumNow ( View Tweet)
RA Disease Activity and Alcohol Use
The effects of alcohol use in RA is less known, but a study suggests that alcohol consumption was dose-dependently associated with lower disease activity and higher health-related quality of life in RA patients.
https://t.co/u6ZjZ7o1Hq https://t.co/S9JPXMJVZo
Links:
Dr. John Cush RheumNow ( View Tweet)
Join RheumNow Live in person or virtually on 3/18 and 3/19. This meeting is unlike any other meeting you attended.
But don't take our word for it, last year's attendees say:
"Great conference. Best in the last year. I did Hopkins, CCR, and ACR too"
https://t.co/Im6xStFwOw https://t.co/NhdbkNo1jl
Links:
Dr. John Cush RheumNow ( View Tweet)
